Asinex announces a one year extension to collaboration with Johnson and Johnson Pharmaceutical research and development, a division of Janssen Pharmaceutica
Asinex, a provider of lead generation and optimisation services, has announced a one year extension to a discovery chemistry agreement with Johnson and Johnson Pharmaceutical Research and Development (J&JPRD), part of the world's largest healthcare company, Johnson and Johnson.
The deal was initially signed in June 2002.
An undisclosed number of Asinex scientists have been working closely with Janssen Pharmaeutica in order to design and synthesise libraries of new compounds.
The collaboration has also included lead optimisation and custom synthesis services.
Dimitri Genis, Asinex's director of research, commented: "The extension of this deal is further proof that Asinex is an effective and reliable provider of lead optimisation and custom synthesis services.
"We are delighted to prolong the agreement for a further year". Asinex is a full-service chemistry provider of intelligent chemistry for the lead generation and optimisation stage of drug discovery.
Well known as a supplier of diverse, small molecule libraries for screening and building blocks for combinatorial chemistry, Asinex say it has developed a reputation for cost-effective and efficient lead optimisation, custom synthesis, and focused library generation.
Kinase, GPCR and ion-channel targeted libraries have recently been launched.
Based in Moscow, with a total of 104 chemists (41 PhDs), 8 computational (6 PhDs) chemists and 17 biologists (11 PhDs), Asinex says it has powerful drug discovery resources.
